Published in:
Open Access
01-12-2013 | Review
B-Raf and the inhibitors: from bench to bedside
Authors:
Tiangui Huang, Michael Karsy, Jian Zhuge, Minghao Zhong, Delong Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2013
Login to get access
Abstract
The B-Raf protein is a key signaling molecule in the mitogen activated protein kinase (MAPK) signaling pathway and has been implicated in the pathogenesis of a variety of cancers. An important V600E mutation has been identified and can cause constitutive B-Raf activation. Recent studies have evaluated a variety of small molecule inhibitors targeting B-Raf, including PLX4032/vemurafenib, dabrafenib, LGX818, GDC0879, XL281, ARQ736, PLX3603 (RO5212054), and RAF265. Therapeutic resistance has been identified and various mechanisms described. This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance.